CRANBURY, N.J., Sept. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2022 operating results on Thursday, September 22, 2022, before the open of the U.S. financial markets.
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 22, 2022, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.
Schedule for the Operating Results Press Release, Conference Call / Audio Webcast |
||
Q4 & Fiscal Year End 2022 Results Press Release |
9/22/2022 at 7:30 a.m. ET |
|
Q4 & Fiscal Year End 2022 Conference Call-Live |
9/22/2022 at 11:00 a.m. ET |
|
US/Canada Dial-In Number: |
1-800-458-4121 |
|
International Dial-In Number: |
1-313-209-6672 |
|
Conference ID: |
8655999 |
|
Q4 & Fiscal Year End 2022 Conference Call-Replay |
9/22/2022-9/29/2022 |
|
US/Canada Dial-In Number: |
1-888-203-1112 |
|
International Dial-In Number: |
1-719-457-0820 |
|
Replay Passcode: |
8655999 |
|
Audio Webcast Live and Replay Access |
http://www.palatin.com |
The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com.
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.
SOURCE Palatin Technologies, Inc.
![](https://rt.prnewswire.com/rt.gif?NewsItemId=PH77325&Transmission_Id=202209191615PR_NEWS_USPR_____PH77325&DateId=20220919)
Share this article